Search Results

function and drug discovery of GPCR signaling Illuminating the understudied GPCR-ome Industry News Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates

Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting

Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation Award) Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Call for

Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds

Facility with Hercules Capital Gene-to-structure and Europe give Proteros customers a winning hand Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for

Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform Sosei Heptares and Neurocrine Biosciences won Top Out-Licensing Deal on the 8th annual Japan Deal of the Year

GPCR-Gi protein complex Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors Industry News Sosei Heptares to take back GPCR agonist after GSK changes course All-rounder among receptors inspires drug

Science Offerings with Multispan Cell Engineering and Assay Services $3bn sales potential for drug Sosei Heptares wants back from GSK Novartis drops subpoena request in trade-secret spat with Takeda Novartis

Fourth Quarter And Full Year 2022 Financial Results And Provides Corporate Update Alastair Brown from Sosei Heptares, will present at the 18th Annual Biomarkers Congress.

Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023 Pioneering

progress its proprietary CCR8 antibody candidate to the clinic Novo strikes another obesity drug deal Sosei Heptares Webinar Presentation for FY2023 Financial Results Novartis Automates New Radioligand Therapy

Industry News The Adrenaline Puzzle Solved: Scientists Untangle Key Cell Receptor's Inner Workings Sosei Heptares to Present at 42nd Annual J.P.

Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change

Medicines for CNS Diseases Addex Reports Full Year 2022 Financial Results and Provides Corporate Update Sosei Heptares Announces the Publication of its Inaugural ESG Report, for the Financial Year ended 31 December

GPCR Therapeutics' latest science paper was published by the American College of Clinical Pharmacology Sosei

spearhead global development and North American expansion as the leading GPCR immuno-oncology company Sosei

Obesity: Likelihood of Approval Septerna to Participate in Upcoming Investor and Industry Conferences Sosei